TMDX - CIK 0001756262
The table below shows TransMedics Group, Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | $192.84M | $48.80M | -$13.03M | -$45.82M | -$28.86M | -$30.27M |
| Capital expenditure | $59.25M | $129.74M | $151.85M | $11.91M | $3.52M | $455.00K |
| Investing cash flow | -$59.25M | -$129.30M | -$193.95M | $54.51M | $29.27M | -$41.60M |
| Dividends paid | - | - | - | - | - |
TransMedics Group, Inc. reported operating cash flow of $192.84M for fiscal year 2025. That is up 295.1% from $48.80M in fiscal 2024. Over the 8 fiscal years shown, operating cash flow grew from -$25.98M (FY 2018) to $192.84M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $16.86M | $22.87M | $400.42M | $167.93M | $1.39M | $75.55M |